Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
CNS Pharmaceuticals, Inc. (CNSP) had Return on Equity of -39.21% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-4.30M |
|
-- |
|
-- |
|
$4.34M |
|
$-4.34M |
|
$0.04M |
|
$-4.30M |
|
$-4.30M |
|
$-4.30M |
|
$-4.30M |
|
$-4.30M |
|
$-4.30M |
|
$-4.34M |
|
$-4.34M |
|
2.73M |
|
2.73M |
|
$-1.58 |
|
$-1.58 |
|
| Balance Sheet Financials | |
$13.72M |
|
$0.00M |
|
$0.03M |
|
$13.75M |
|
$2.78M |
|
-- |
|
-- |
|
$2.78M |
|
$10.97M |
|
$10.97M |
|
$10.97M |
|
2.94M |
|
| Cash Flow Statement Financials | |
$-3.24M |
|
-- |
|
$9.83M |
|
$6.46M |
|
$13.05M |
|
$6.59M |
|
$0.06M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.94 |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-3.24M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-39.21% |
-39.21% |
|
-31.28% |
|
-39.21% |
|
$3.73 |
|
$-1.19 |
|
$-1.19 |
|